ITGAE and neoplasm: The proposed mechanism of action is that that CD103+ cross-presenting DCs are functionally impaired in a high-adenosine tumor environment; thus, antagonizing A2AR using AZD4635 can reverse adenosine-mediated immunosuppression, leading to improved T cell function and enhanced anti-tumor immunity [163].